^
Association details:
| Biomarker: | HER-2 positive |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) (HER2 inhibitor, HER2 dimerization inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Chugai Obtains Regulatory Approval for Phesgo, the Fixed-Dose Subcutaneous Combination of Perjeta and Herceptin for HER2-Positive Breast and Colorectal Cancer
Published date:
09/25/2023
Excerpt:
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) announced that it has obtained regulatory approval today from the Ministry of Health, Labour and Welfare (MHLW) for Phesgo® combination for Subcutaneous Injection MA, IN [generic name: pertuzumab (genetical recombination), trastuzumab (genetical recombination) and vorhyaluronidase alfa (genetical recombination) ] (hereafter, Phesgo), antineoplastic agent / anti-HER2 humanized monoclonal antibody for the treatment of “HER2-positive breast cancer” and “Advanced or recurrent HER2-positive colorectal cancer that has progressed following cancer chemotherapy and is not amenable to curative resection.”
